Progyny, Inc.

Listed Company

PGNYCIK 0001551306NasdaqLarge AcceleratedServices-Misc Health & Allied Services, NecDelawareFY ends Dec 31

Period

FY 2025

Revenue

$1.29B

Net Income

$58.52M

Total Assets

$742.43M

Equity

$516.04M

Shares Out

78.33M

Op. Cash Flow

$210.19M

PGNY$31.90+38.64% · past yearDBEQ Basic

Daily closing prices

Business

Progyny is a global leader in employer-sponsored women's health and family building benefits solutions. The company provides a comprehensive platform including fertility benefits (via its proprietary Smart Cycle design), pregnancy and postpartum support, menopause and midlife solutions, benefit and leave navigation, parent and child wellbeing programs, and Progyny Rx (integrated pharmacy benefits). Progyny serves over 590 employers across more than 40 industries covering approximately 7.2 million employees and their dependents through a model combining personalized concierge support, a selective network of 1,100+ fertility specialists, data-driven outcomes tracking, and integrated care coordination.

Summary from 10-K filed 2026-02-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	1,289	1,167	1,089	787	501
Cost of services	984	914	850	620	388
Gross profit	304	253	239	167	112
Sales and marketing	72	64	59	46	20
General and administrative	147	122	117	98	60
Total operating expenses	219	186	177	144	80
Income from operations	85	67	62	23	32
Interest and other income, net	10	16	9	1	−366,000
Income before income taxes	95	83	71	24	32
Provision for income taxes	37	29	9	−6	−33
Net income	59	54	62	30	66
Basic (in dollars per share)	0.68	0.59	0.65	0.33	0.74
Diluted (in dollars per share)	0.65	0.57	0.62	0.3	0.66
Basic (in shares)	86	91	95	92	89
Diluted (in shares)	90	95	101	100	100

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	112	162	97	120	91
Marketable securities	198	66	274	69	28
Accounts receivable, net of $55,659 and $56,355 of allowances at December 31, 2025 and 2024, respectively	220	235	242	240	135
Prepaid expenses and other current assets	21	9	27	4	5
Total current assets	552	473	640	434	259
Property and equipment, net	30	12	10	8	5
Operating lease right-of-use assets	25	17	18	7	8
Goodwill	20	16	12	12	12
Intangible assets, net	6	1	0	99,000	599,000
Deferred tax assets, net	93	85	73	78	71
Other noncurrent assets	17	3	3	4	3
Total assets	742	607	757	543	358
Accounts payable	124	95	125	109	61
Accrued expenses and other current liabilities	78	74	61	50	37
Total current liabilities	202	169	186	160	99
Operating lease noncurrent liabilities	24	16	17	6	7
Total liabilities	226	185	203	166	106
Commitments and Contingencies (Note 15)	—	—	—	—	—
Common stock, $0.0001 par value; 1,000,000,000 shares authorized; at December 31, 2025 and 2024, respectively; 99,049,485 and 97,692,891 shares issued; 83,365,696 and 85,310,698 outstanding at December 31, 2025 and 2024, respectively	9,000	9,000	9,000	9,000	9,000
Additional paid-in capital	701	582	462	350	255
Treasury stock, at cost, $0.0001 par value; 16,299,769 and 12,998,173 shares at December 31, 2025 and 2024, respectively	−388	−304	−1	−1	−1
Accumulated earnings	203	144	90	28	−2
Accumulated other comprehensive income	498,000	39,000	3	501,000	−93,000
Total stockholders equity	516	422	553	377	252
Total liabilities and stockholders equity	742	607	757	543	358

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net income	59	54	62	30	66
Deferred tax (benefit) expense	−8	−10	4	−7	−33
Non-cash interest expense (income)	434,000	0	−34,000	—	—
Depreciation and amortization	5	3	2	2	1
Loss on disposal of property and equipment	100,000	1	0	0	—
Stock-based compensation expense	132	128	123	101	34
Bad debt expense	21	16	20	14	10
Net accretion of discounts on marketable securities	−866,000	−2	−4	0	0
Foreign currency exchange rate loss	0	0	−8,000	0	0
Accounts receivable	−5	−10	−22	−119	−69
Prepaid expenses and other current assets	−12	18	−23	57,000	675,000
Accounts payable	29	−30	16	48	18
Accrued expenses and other current liabilities	417,000	10	10	13	2
Other noncurrent assets and liabilities	−9	425,000	648,000	−1	−3
Net cash provided by operating activities	210	179	189	80	26
Purchase of property and equipment, net	−18	−5	−4	−3	−2
Purchase of marketable securities	−355	−170	−430	−163	−111
Sale of marketable securities	224	377	233	123	122
Acquisition of business, net of cash acquired	−9	−5	0	0	—
Net cash (used in) provided by investing activities	−159	196	−201	−44	9
Repurchase of common stock	−82	−300	0	0	—
Proceeds from exercise of stock options	86,000	1	5	3	3
Issuance costs on credit facility	−3	0	0	—	—
Payment of employee taxes related to equity awards	−16	−12	−17	−12	−18
Proceeds from contributions to employee stock purchase plan	1	1	1	1	1
Net cash used in financing activities	−99	−310	−11	−8	−14
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	62,000	1,000	1,000	—	—
Net (decrease) increase in cash, cash equivalents, and restricted cash	−48	65	−23	29	21
Cash paid for income taxes, net of refunds received	55	40	6	133,000	97,000
Additions of property and equipment, net included in accounts payable and accrued expenses	681,000	249,000	421,000	636,000	204,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Progyny, Inc.'s CIK number?

Progyny, Inc.'s SEC CIK number is 0001551306 (1551306). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Progyny, Inc.'s SEC filings?

All of Progyny, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Progyny, Inc. last report earnings?

Progyny, Inc. (PGNY) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001551306-26-000062). This is Progyny, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Progyny, Inc.'s most recent earnings 8-K?

Progyny, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001551306-26-000062. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Progyny, Inc.'s latest earnings 8-K →
Look up any company's CIK number →